Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ensartinib”

30 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 30 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05491811
What this trial is testing

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 49
Not applicableNot Yet RecruitingNCT06736561
What this trial is testing

Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.

Who this might be right for
ALK PositiveEnsartinibNSCLC+1 more
Harbin Medical University 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT03753685
What this trial is testing

X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Who this might be right for
Nonsmall Cell Lung CancerBrain Metastases
Fudan University 27
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07235306
What this trial is testing

Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC

Who this might be right for
NSCLC Stage IIIEnsartinibChemoradiotherapy+1 more
Shanghai Pulmonary Hospital, Shanghai, China 45
Post-approval studies (Phase 4)Not Yet RecruitingNCT06785584
What this trial is testing

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study

Who this might be right for
ALK-positive Advanced NSCLCALK-positive Non-small Cell Lung Cancer (NSCLC)MPR+1 more
Fujian Medical University Union Hospital 30
Early research (Phase 1)Study completedNCT03510611
What this trial is testing

Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 24
Large-scale testing (Phase 3)Active Not RecruitingNCT02767804
What this trial is testing

EXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung Cancer
Xcovery Holdings, Inc. 290
Testing effectiveness (Phase 2)Study completedNCT02898116
What this trial is testing

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerCarcinomaNSCLC
Ludwig Institute for Cancer Research 2
Not applicableLooking for participantsNCT05498064
What this trial is testing

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma Kinase I1171NEnsartinib
Peking Union Medical College Hospital 490
Testing effectiveness (Phase 2)Active Not RecruitingNCT03420508
What this trial is testing

Treating Patients With Melanoma and ALK Alterations With Ensartinib

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06772610
What this trial is testing

The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors

Who this might be right for
NSCLCALKStage I+1 more
Shanghai Pulmonary Hospital, Shanghai, China 40
Large-scale testing (Phase 3)Looking for participantsNCT05341583
What this trial is testing

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 202
Early research (Phase 1)UnknownNCT03804541
What this trial is testing

The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human

Who this might be right for
ALK-POSITIVE NSCLC
Betta Pharmaceuticals Co., Ltd. 6
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06779539
What this trial is testing

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
West China Hospital 33
Early research (Phase 1)Study completedNCT05665283
What this trial is testing

A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions

Who this might be right for
Bioequivalency
Xcovery Holdings, Inc. 32
Early research (Phase 1)Study completedNCT03536481
What this trial is testing

Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers

Who this might be right for
Lung Cancer
Betta Pharmaceuticals Co., Ltd. 74
Testing effectiveness (Phase 2)UnknownNCT05380024
What this trial is testing

Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Peking University Cancer Hospital & Institute 10
Early research (Phase 1)Not Yet RecruitingNCT06492525
What this trial is testing

Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers

Who this might be right for
Healthy
Betta Pharmaceuticals Co., Ltd. 36
Testing effectiveness (Phase 2)UnknownNCT05178511
What this trial is testing

Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance

Who this might be right for
The Diagnosis Was ALK Positive NSCLCSecond Generation ALK-TKI is ResistantEfficacy of Ensatinib in This Subset of Patients
Li Zhang, MD 40
Not applicableAvailableNCT04146571
What this trial is testing

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Who this might be right for
Non-Small Cell Lung CancerALK Gene Rearrangement Positive
Xcovery Holdings, Inc.
Load More Results